Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for Injecting Drug Users

Overview

Journal MMWR Morb Mortal Wkly Rep

Date 2013 Jun 14

PMID 23760186

Citations 54

Affiliations

Soon will be listed here.

Abstract

On June 12, 2013, the Thailand Ministry of Health and CDC published results from a randomized controlled trial of a daily oral dose of 300 mg of tenofovir disoproxil fumarate (TDF) that showed efficacy in reducing the acquisition of human immunodeficiency virus (HIV) infection among injecting drug users (IDUs) (1). Based on these findings, CDC recommends that preexposure prophylaxis (PrEP) be considered as one of several prevention options for persons at very high risk for HIV acquisition through the injection of illicit drugs.

Citing Articles

Investigating facilitators and barriers to the routine provision of HIV PrEP in community pharmacies in London.

Alter M, Lakhani S, Alaa A, Karki M, Riboli-Sasco E, El-Osta A BMC Health Serv Res. 2025; 25(1):312.

PMID: 40001055 PMC: 11863588. DOI: 10.1186/s12913-025-12336-1.

Uptake of Human Papillomavirus Vaccination by HIV Status and HIV Pre-exposure Prophylaxis (PrEP) Care Engagement Among Young Sexual Minority Men 17-24 Years Old in the USA.

Pleuhs B, Walsh J, Quinn K, Petroll A, Nyitray A, John S Sex Res Social Policy. 2023; 19(4):1944-1953.

PMID: 36687804 PMC: 9857745. DOI: 10.1007/s13178-022-00740-9.

Evidence of Potential Discriminatory HIV Pre-Exposure Prophylaxis (PrEP) Prescribing Practices for People Who Inject Drugs Among a Small Percentage of Providers in the U.S.

Pleuhs B, Mistler C, Quinn K, Dickson-Gomez J, Walsh J, Petroll A J Prim Care Community Health. 2022; 13:21501319211063999.

PMID: 35068243 PMC: 8796077. DOI: 10.1177/21501319211063999.

HIV Pre-Exposure Prophylaxis Prevention Awareness, Willingness, and Perceived Barriers among People Who Inject Drugs in Los Angeles and San Francisco, CA, 2016-2018.

Walters S, Kral A, Simpson K, Wenger L, Bluthenthal R Subst Use Misuse. 2020; 55(14):2409-2419.

PMID: 32962490 PMC: 7665852. DOI: 10.1080/10826084.2020.1823419.

A Narrative Review of Continuing Professional Development Needs for Pharmacists with Respect to Pre-exposure Prophylaxis (PrEP) for Human Immunodeficiency Virus (HIV).

Wilby K, Smith A Pharmacy (Basel). 2020; 8(2).

PMID: 32403459 PMC: 7356600. DOI: 10.3390/pharmacy8020084.

References

Thigpen M, Kebaabetswe P, Paxton L, Smith D, Rose C, Segolodi T . Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012; 367(5):423-34. DOI: 10.1056/NEJMoa1110711. View

. Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. MMWR Morb Mortal Wkly Rep. 2012; 61(31):586-9. View

Edelman E, Fiellin D . Moving HIV pre-exposure prophylaxis into clinical settings: lessons from buprenorphine. Am J Prev Med. 2012; 44(1 Suppl 2):S86-90. PMC: 3645931. DOI: 10.1016/j.amepre.2012.09.035. View

. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep. 2011; 60(3):65-8. View

Baeten J, Donnell D, Ndase P, Mugo N, Campbell J, Wangisi J . Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012; 367(5):399-410. PMC: 3770474. DOI: 10.1056/NEJMoa1108524. View